New hope for Hard-to-Treat breast cancer: drug combo trial launches
Disease control
Recruiting now
This study tests a new combination of two drugs (lasofoxifene and abemaciclib) against a standard combination (fulvestrant and abemaciclib) for people with advanced ER+/HER2- breast cancer that has a specific mutation (ESR1). About 500 adults whose cancer worsened after initial h…
Phase: PHASE3 • Sponsor: LeonaBio • Aim: Disease control
Last updated May 06, 2026 16:15 UTC